JPMorgan Chase & Co. Reiterates “GBX 1,320” Price Target for GlaxoSmithKline (GSK)
GlaxoSmithKline (LON:GSK) has been assigned a GBX 1,320 ($18.24) target price by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Monday. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s target price suggests a potential upside of 2.25% from the company’s previous close.
GSK has been the subject of several other research reports. Goldman Sachs Group reissued a “buy” rating and set a GBX 1,900 ($26.25) price objective on shares of GlaxoSmithKline in a research report on Tuesday, October 17th. S&P Global set a GBX 1,500 ($20.72) price objective on GlaxoSmithKline and gave the company a “neutral” rating in a research report on Thursday, October 26th. HSBC reissued a “buy” rating and set a GBX 1,925 ($26.60) price objective on shares of GlaxoSmithKline in a research report on Wednesday, November 22nd. Morgan Stanley set a GBX 1,450 ($20.03) price objective on GlaxoSmithKline and gave the company a “sell” rating in a research report on Monday, November 6th. Finally, Kepler Capital Markets lowered their price objective on GlaxoSmithKline from GBX 1,520 ($21.00) to GBX 1,340 ($18.51) and set a “reduce” rating for the company in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 1,540.45 ($21.28).
GlaxoSmithKline (LON GSK) opened at GBX 1,291 ($17.84) on Monday. The company has a market capitalization of $64,010.00 and a price-to-earnings ratio of 4,164.52. GlaxoSmithKline has a 52-week low of GBX 1,235.20 ($17.07) and a 52-week high of GBX 1,724.50 ($23.83).
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.